The global dyslipidemia drugs market size is projected to expand at a robust CAGR during the forecast period, 2021–2028. The growth of the market is attributed to growing prevalence of cholesterol abnormalities and lipid associated disorders.
Dyslipidemia is a condition encompasses of changes in the level of lipids in the blood. Growing prevalence of cholesterol abnormalities and lipid associated disorders is expected to witness a positive influence in the market. This includes inability of the body to metabolize fats, triglyceride abnormalities, and bio molecular high lipid content. Rising geriatric population globally is expected to be more vulnerable to cardiovascular diseases and is the major factor estimated to drive the market. Cholesterol related diseases alternatively lead to heart failure and coronary diseases. CDC estimated that, heart failure is one of the main reason of death worldwide. Therefore, there is a high demand for innovation in treatment of disorder progression at the early stage and therefore mark mortality rates.
Market Trends, Drivers, Restraints, and Opportunities
- Growing prevalence of cholesterol abnormalities and lipid related disorders are the key factors driving the market.
- Rising global geriatric population which is more vulnerable to cardiovascular diseases is expected to accelerate the market in the coming years.
- Upcoming biotechnological products for instance, monoclonal antibodies for treatment of lipid disorders are estimated to fuel the market.
- Unmet medical need for the treatment of lipid related disorders and heart diseases is expected to boost the market during the forecast period.
- High capital demand for biotechnology-based R&D drug innovation is expected to hamper the market growth.
Scope of the Report
The report on the dyslipidemia drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Dyslipidaemia Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Products (Statins, Bile Acid Sequesterants [Colesevelam, Cholestyramine, Cholybar, and Colestipol], Niacin, Fibric Acid Derivatives, and Cholesterol Absorption Inhibitors)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Pfizer, Inc.; Abbott Laboratories; Merck & Co., Inc.; Novartis AG; Amgen, Inc.; Astra Zeneca Plc; and Mylan N.V.
|
Market Segment Insights
The statins segment is expected to grow at a rapid pace
Based on products, the global dyslipidemia drugs market is segregated into statins, bile acid sequesterants, niacin, fibric acid derivatives, and cholesterol absorption inhibitors. The bile acid sequesterants segment is further classified into colesevelam, cholestyramine, cholybar, and colestipol. The statins segment accounts for a key share of the market owing to prescription of statins and widespread usage; however, the bile acid sequesterants segment is anticipated to expand at a rapid pace during the forecast period due to large array of pipeline drugs that are under clinical trial phases of development.
North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market owing to rising incidence of diabetes and obesity. The market of Asia Pacific is anticipated to expand at a rapid pace during the forecast period owing to biotechnological developments and improvement in health care infrastructure.
Segments
The global dyslipidemia drugs market has been segmented on the basis of
Products
- Statins
- Bile Acid Sequesterants
- Colesevelam
- Cholestyramine
- Cholybar
- Colestipol
- Niacin
- Fibric Acid Derivatives
- Cholesterol Absorption Inhibitors
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Pfizer, Inc.
- Abbott Laboratories
- Merck & Co., Inc.
- Novartis AG
- Amgen, Inc.
- Astra Zeneca Plc.
- Mylan N.V
Competitive Landscape
Key players competing in the dyslipidemia drugs market include Pfizer, Inc.; Abbott Laboratories; Merck & Co., Inc.; Novartis AG; Amgen, Inc.; Astra Zeneca Plc.; and Mylan N.V.
Some of these players are using several market strategies such as acquisitions, merger, collaborations, partnerships, capacity expansion, and product launches to enhance their market shares and to generate revenue and raise their production line of the business in the coming years.
Request For Customization
Enquiry Before Buying
Speak With Analyst
